ACCEDI

Per proseguire, inserisci il nome utente (mail di registrazione) e la password del tuo account AccMed Online.

REGISTRATI

Se non hai un account AccMed Online, registrati ora gratuitamente.

AccMed Online è l’account gratuito che permette di iscriversi e partecipare alle attività formative (su fad.accmed.org) e di accedere agli altri servizi digitali di Accademia Nazionale di Medicina.

 

 

Abstracts from ASH 2019



Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma 

Robert J Lin, et al.

Older patients should not be excluded from CAR T based on chronologic age alone; these results highlight potential benefits of CAR T in selected older patients even with functional limitation, multi-morbidity, and significant tumor burden; and the lack of excessive CRS, NT, and other high-grade toxicities.

Abstract n. 1603

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Samantha Jaglowski, et al.

In the real-world, tisa-cel has similar efficacy and improved safety in DLBCL patients. OOS product (viability 60-80%) does not impact efficacy

Abstract n. 766

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry

Stephan Grupp, et al.

In the real-world, tisa-cel has similar efficacy and improved safety in pediatric ALL patients. OOS product (viability 60-80%) does not impact efficacy

Abstract n. 2619

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England 

Andrea Kuhnl, et al.

In this study, 122 patients were treated with axicabtagene ciloleucel and tisagenlecleucel. Details on bridging therapy, treatment-related toxicities and outcomes will be provided at the meeting, by which time 62 patients will have completed their 3 months PET response assessment

Abstract n. 767

Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age ≥65 Years

Marjorie E Zettler, et al.

This large-scale post-marketing report of CAR T-cell therapy associated AEs provides real-world evidence for use of CAR T-cell therapy in patients ≥65 and reports patterns of AEs observed based on age.

Abstract n. 1951